Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 19/20 | 0.59 |
| ▸ | LATS2 | Q9NRM7 | 17/20 | 0.59 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065225 | 1.00 | LATS1 (0.59) | LATS1LATS2CDC7 | |
| SCHEMBL15644598 | 0.84 | LATS1 (0.44) | LATS1LATS2 | |
| SCHEMBL24746836 | 0.84 | CDC7 (0.47) | LATS1LATS2CDC7 | |
| SCHEMBL30064150 | 0.84 | CDC7 (0.47) | LATS1LATS2CDC7 | |
| SCHEMBL20547439 | 0.84 | LATS1 (0.62) | LATS1LATS2 | |
| SCHEMBL19880933 | 0.82 | LATS1 (0.45) | LATS1LATS2 | |
| SCHEMBL16908289 | 0.81 | LATS1 (0.43) | LATS1LATS2CDC7 | |
| SCHEMBL30064444 | 0.81 | LATS1 (0.43) | LATS1LATS2CDC7 | |
| SCHEMBL24746631 | 0.81 | LATS1 (0.43) | LATS1LATS2CDC7 | |
| SCHEMBL29650615 | 0.81 | LATS1 (0.43) | LATS1LATS2CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | GENENTECH, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2022253341-A1 | 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS | GENENTECH, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-3129372-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-2900666-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-11-04 | — | — | EP | disclosed |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914730-B2 | Azaquinazoline inhibitors of Atypical protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9896446-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-02-20 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2015148597-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2014052699-A9 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | LATS1 1164/4885LATS2 1387/4885CDC7 170/4885 |
| US-20240174696-A1 | 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS | LATS1, LATS2, GLS2 | LATS1 1/4885LATS2 2/4885CDC7 179/4885 |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | PRKCQ, PRKCA, PRKCZ | LATS1 900/4885LATS2 1220/4885CDC7 207/4885 |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | PRKCQ, PRKCA, PRKCZ | LATS1 900/4885LATS2 1220/4885CDC7 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.